Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study-Reference-Cited by-同舟云学术

Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study

Published:2003-05-21 Issue:6 Volume:1 Page:1208-1214
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

Bladbjerg E. M.,Madsen J. S.,Kristensen S. R.,Abrahamsen B.,Brixen K.,Mosekilde L.,Jespersen J.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1538-7836.2003.00281.x/fullpdf

Reference32 articles.

1. Hormone replacement therapy, heart disease, and other considerations;Barrett-Connor;Annu Rev Public Health,1998

2. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women;Hulley;JAMA,1998

3. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II);Grady;JAMA,2002

4. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial;Writing group for the Women's Health Initiative Investigators.;JAMA,2002

5. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK haemostasis study;Salomaa;Arterioscler Thromb Vasc Biol,1995

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of tissue factor pathway inhibitor in hormone-induced venous thromboembolism;Blood Coagulation & Fibrinolysis;2023-04-13

2. Sex differences in ischaemic stroke: potential cellular mechanisms;Clinical Science;2017-03-17

3. Endothelium-Dependent Hemostatic Factors in Women with Previous Gestational;Turkish Journal of Endocrinology and Metabolism;2016-06-23

4. Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy;Arteriosclerosis, Thrombosis, and Vascular Biology;2016-02

5. Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis;The Journal of Clinical Endocrinology & Metabolism;2015-11-01